You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞信窩輪》中移偏軟藥股強勢,留意中移購11976、石藥購11412
阿思達克 12-23 13:28

落後股中移動(0941)上周五突受追捧後,不過周一無以為繼,股價及後輕微偏軟。中移動上月上客量按月升逾89%,向上觀望突破65元的機會,支持參考50天線約62.6元。看好可留意中移購11976,行使價73.55元,20年3月到期。或中移牛52600,收回價58.28元,行使價57.08元,20年4月到期。

手機設備股舜宇光學(2382)周一低位曾失守135元,觀望反彈,看好可留意舜光購12949,行使價166.68元,20年5月到期。或舜光牛64276,收回價124.88元,行使價120.88元,20年11月到期。相反看淡可留意舜光沽12814,行使價119.88元,20年5月到期。或舜光熊64527,收回價154.88元,行使價158.88元,20年11月到期。

瑞聲科技(2018)周一則升逾1%,一度重返66元以上。看好可留意瑞聲購15032,行使價76.78元,20年6月到期。相反看淡可留意瑞聲沽13452,行使價57.88元,20年7月到期。

醫藥股續向上,石藥集團(1093)周一升約2%,曾重上18.6元。看好可考慮石藥購11412,行使價19.82元,20年2月到期。或石藥牛61638,收回價16.68元,行使價15.98元,20年6月到期。相反看淡可留意石藥沽12763,行使價17.78元,20年5月到期。或石藥熊61973,收回價21.08元,行使價21.78元,20年6月到期。

中國生物製藥(1177)周一同樣升逾2%,高位重上11元。看好可考慮中藥購13876,行使價12.18元,20年6月到期。或中藥牛62532,收回價9.38元,行使價8.98元,20年9月到期。相反看淡可留意中藥沽24621,行使價9.08元,20年3月到期。

(本結構性產品並無抵押品)

《瑞信香港認股證及牛熊證銷售主管何啟聰》

免責聲明:筆者為瑞士信貸(香港)有限公司的代表 ,並身為證監會持牌人,並無持有相關上市公司的任何財務權益。本文內容僅供參考,並不構成要約、建議或促使任何人士提呈買賣或認購任何證券。結構性產品價格可急升或急跌,投資者或會蒙受全盤損失。本產品並無抵押品。如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。牛熊證備強制贖回機制而可能被提早終止,屆時(i)N類牛熊證投資者將不獲發任何金額;而(ii)R類牛熊證之剩餘價值可能為零。有關恆生指數或恆生中國企業指數的免責聲明,請參閱上市文件。過往表現並不反映將來表現。投資前,投資者應瞭解風險,並諮詢專業顧問及查閱有關上市文件。瑞信之聯屬公司為結構性產品之流通量提供者,亦可能是唯一報價者。本文任何內容概不構成投資、法律、會計或稅務意見、並無聲明任何投資或策略適合或符合閣下的個別情況。結構性產品交投量並不是結構性產品表現的指標,投資者不應僅依賴交投量歷史高位數據以釐定結構性產品日後的表現。~重要聲明:

以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account